German Remedies to market Bio Sidus’ oncology product in India

German Remedies to market Bio Sidus’ oncology product in India

Balakrishnan Nair – Mumbai

German Remedies, a wholly-owned subsidiary of Cadila Healthcare, has inked an agreement with Argentina-based Bio Sidus to market the latter’s oncology drug Colstim (filgrastim) in India.

J C Jani, Managing Director, German Remedies told Express Pharma Pulse, ‘‘Colstim, a supportive therapy for cancer, is being launched this month. The drug being an adjuvant therapy minimises the toxic effects of myelosuppressive chemotherapy.’’

‘‘The product is an offering from our critical care unit. Our other divisions include pharma, diagnostic, respiratory, generics and women healthcare. The critical care unit comprises products mainly for heart disorders, cancer etc.’’

‘‘Colstim has been registered in 17 countries. With this product, the company expects to garner around 10 per cent share of the market which is currently worth Rs 25 crore,” said B V Ramana, National Sales and Marketing Manager, German Remedies.

“Unlike other products available in the market, Colstim is a liquid injectable and in ready-to-use form. There is no need for distilled water to reconstitute it.’’ Filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. It is a man-made form of granulocyte colony-stimulating factor (G-CSF), which is made using the bacteria E coli. G-CSF is a substance naturally produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.

‘‘Further, Colstim reduces duration and severity of neutropenia, reduces incidence of febrile neutropenia, infections, hospitalisation days and use of antibiotics and can be administered to out-patients,’’ said Prasen Adya, Senior Product Manager, Critical Care Unit. Neutropenia is a condition where the body makes too few white blood cells. It may be a long-standing condition where the body does not make enough white blood cells, or it may be caused by drugs used to treat cancer.

From this unit the company markets products like Acetyle salicylic acid, Catapres (Boehringer Ingelheim), Ildamen (Asta Medica), Nivant for heart disorders and hypertension, Dobixin injection for cancer, Persantin (Boehringer Ingelheim), Endoxan (Asta Medica), Holoxan (Asta Medica), Honvan injections and tablets (Asta Medica), Platicis and Uromitexan (Asta Medica).

Neutropenia is a condition where the body makes too few white blood cells. It may be a long-standing condition where the body does not make enough white blood cells, or it may be caused by drugs used to treat cancer.

Biosidus, the biotech arm of Sidus, is the first company to develop human growth hormones from the milk of cloned transgenic cows.

The drug is made available in the injectable form and is priced Rs 2400 for 300 mcg vial. This is the first strategic alliance with the Argentian drug maker Sidus and many more launches are expected from their stable.

—balakrishnannair@expressindia.com